NCT06644378

A Study of [14C]-LY3866288 in Healthy Participants

A Phase 1, Open-label, 2-part Study of the Absorption, Metabolism, and Excretion, and Absolute Bioavailability of [14C]-LY3866288 in Healthy Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to evaluate how much of the study drug (LY3866288), administered as a single dose that has the radioactive substance 14C incorporated into it, passes from blood into urine, feces and expired air in healthy participants. The study will also measure how much of the study drug gets into the bloodstream when taken orally, compared to when injected directly into the vein, how its broken down, and how long it takes the body to get rid of it. The study will also evaluate the safety and tolerability of LY3866288.The study is conducted in two parts. The study is expected to last approximately 68 days.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	[14C]-LY3866288	Administered orally.
DRUG	LY3866288	Administered orally.
DRUG	[14C]-LY3866288	Administered IV.

Timeline

• Start date: 2024-10-28
• Primary completion: 2025-01-03
• Completion: 2025-01-03
• First posted: 2024-10-16
• Last updated: 2025-01-22

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study